View all Oncology Consultations CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit

Acknowledgment of Commercial Support

This activity is supported by educational grants from Genomic Health and Foundation Medicine.

Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm - PER Pulse™ Recaps
Banner Image

Resources

Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm
Earn up to 2.0 AMA PRA Category 1 Credits
This activity is structured using the Oncology Consultation® platform which features audio clips of two breast cancer experts engaging in case-based discussions of patient management and treatment issues. This educational program features two clinical scenarios that touch upon issues of HER2 equivocal status, molecular profiling for adjuvant decision making, emerging molecular assays for assessment of clinical trial eligibility in the metastatic setting, and germline testing in triple-negative breast cancer. Interactive questions are integrated throughout the cases to reinforce learning.

PER Pulse™ Recaps
Two PER Pulse™ Recaps presenting key elements of the Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm online CME activity.
 



PER Pulse™ Recap

PER Pulse™ Recap
Medical Writer: Kim Farina, PhD


1 of 2
PER Pulse™ Recap:

Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm

The interactive, online CME activity, Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm, features audio recordings of 2 case presentations and commentary by breast cancer experts Drs. Debu Tripathy and Joyce O’Shaughnessy on contemporary issues confronted by medical oncologists as they implement precision medicine in their practices.

This first of 2 PER Pulse™ Recaps summarizing the program focuses on the case of a woman initially diagnosed with ER+, PR+, HER2-equivocal, classical invasive lobular breast cancer at 45 years of age. After 5 years of therapy (2-3 years tamoxifen, bilateral salpingo-oopherectomy, and anastrozole), she developed metastatic recurrence for which she received three lines of therapy (exemestane + everolimus, capecitabine, and nab-paclitaxel). She derived short durations of benefit from each line of therapy for her metastatic disease. Notably, over the course of this case, enrichment of HER2 amplification in residual disease became apparent - the HER2 FISH ratio continuously rose, manifested by a rise in the average number of HER2 gene copies per cell, while the CEP17 average gene copy number remained fairly low. She is now experiencing an excellent response to the CLEOPATRA regimen (docetaxel/trastuzumab + pertuzumab).

Drs. Tripathy and O’Shaughnessy reviewed how this case was managed years ago, and how their approach might differ today and in the future, in terms of assessment of HER2 status, use of molecular profiling for adjuvant decision-making, and application of emerging molecular assays for assessment of clinical trial eligibility in the metastatic setting. Throughout the activity, relevant current guideline recommendations and clinical trial data are emphasized.



2 of 2
PER Pulse™ Recap:

Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm

The interactive, online CME activity, Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm, features audio recordings of 2 case presentations and commentary by breast cancer experts Drs. Debu Tripathy and Joyce O’Shaughnessy on contemporary issues confronted by medical oncologists as they implement precision medicine in their practices.

This second of 2 PER Pulse™ Recaps summarizing the program focuses on the case of a 58-year-old woman with a family history of breast cancer who presents with a newly-diagnosed, 1.7 cm, T1c N0 M0, high-grade, triple-negative breast tumor. Tests for BRCA1/2 mutations and large genomic rearrangements, as well as expanded panel testing, were negative. The patient responded to initial doxorubicin, cyclophosphamide, paclitaxel (ACT), but developed liver and adrenal TNBC metastases 1-year post therapy.

Drs. Tripathy and O'Shaughnessy discuss their general approaches toward genetic testing, including new expanded panel testing, at initial diagnosis and recurrence. They review appropriate treatment strategies for this patient who experienced rapid recurrence after ACT. They also share their perspectives on investigational strategies that triage patients to specific clinical trials based on the findings of gene sequencing studies (eg, androgen receptor (AR)-targeted therapy for AR-positive tumors, immunotherapy for tumors with immune infiltrates, and Poly(ADP-ribose) polymerase inhibition for patients with a homologous DNA repair pathway abnormality). Throughout the activity, relevant current guideline recommendations and clinical trial data are emphasized.

For additional commentary about this case and others, visit www.gotoper.com to access archived audio of Drs Tripathy and O’Shaughnessy from Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment Paradigm.




Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

This activity is supported by educational grants from Genomic Health and Foundation Medicine.





Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By